ANDA Reformulations Should Not Result In Loss Of 180-Day Exclusivity - Andrx
Executive Summary
Reformulation of a product under ANDA review should not result in the loss of 180-day exclusivity eligibility, Andrx argued in Oct. 5 comments to FDA's 180-day generic exclusivity proposed rule.
You may also be interested in...
Patent Litigation Settlements Should Be Filed With FDA, FTC Says
FDA's 180-day ANDA exclusivity rule should require patent litigation settlements between branded companies and ANDA applicants to be filed with FDA, the Federal Trade Commission suggested in comments on FDA's proposed rule.
Patent Litigation Settlements Should Be Filed With FDA, FTC Says
FDA's 180-day ANDA exclusivity rule should require patent litigation settlements between branded companies and ANDA applicants to be filed with FDA, the Federal Trade Commission suggested in comments on FDA's proposed rule.
Purepac Challenges Andrx Cardia XT Exclusivity On Reformulation Grounds
A first-to-file ANDA applicant should lose its eligibility for 180-day exclusivity if it makes major changes to the application at a later date, Purepac asserts in a petition to FDA requesting that Andrx be stripped of its exclusivity for generic sustained-release diltiazem, equivalent to Hoechst Marion Roussel's Cardizem CD.